3B BlackBio DX Intrinsic Value
3BBLACKBIO Valuation Methods Summary
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹842.40 | ₹673.92 - ₹1010.88 | -47.7% | EPS: ₹70.20, Sector P/E: 12x |
| Book Value Method | asset | ₹322.42 | ₹290.18 - ₹354.66 | -80.0% | Book Value/Share: ₹301.11, P/B: 1.0x |
| Revenue Multiple Method | revenue | ₹483.63 | ₹435.27 - ₹531.99 | -70.0% | Revenue/Share: ₹173.33, P/S: 0.8x |
| EBITDA Multiple Method | earnings | ₹644.84 | ₹580.36 - ₹709.32 | -60.0% | EBITDA: ₹80.00Cr, EV/EBITDA: 6x |
| Simple DCF (5Y) | dcf | ₹644.84 | ₹515.87 - ₹773.81 | -60.0% | CF Growth: 5.0%, Discount: 15% |
| PEG Ratio Method | growth | ₹483.63 | ₹435.27 - ₹531.99 | -70.0% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹578.45 | ₹520.61 - ₹636.30 | -64.1% | Revenue Growth: 6.0%, Adj P/E: 8.2x |
| ROE Based Valuation | profitability | ₹1066.67 | ₹960.00 - ₹1173.34 | -33.8% | ROE: 22.1%, P/E Multiple: 16x |
| Graham Defensive Method | conservative | ₹602.22 | ₹542.00 - ₹662.44 | -62.6% | EPS: ₹70.20, BVPS: ₹301.11 |
Want to compare with current market value? Check 3BBLACKBIO share price latest .
Valuation Comparison Chart
3BBLACKBIO Intrinsic Value Analysis
What is the intrinsic value of 3BBLACKBIO?
Based on our comprehensive analysis using 9 different valuation methods, the estimated intrinsic value of 3B BlackBio DX (3BBLACKBIO) is ₹602.22 (median value). With the current market price of ₹1612.10, this represents a -62.6% variance from our estimated fair value.
The valuation range spans from ₹322.42 to ₹1066.67, indicating ₹322.42 - ₹1066.67.
Is 3BBLACKBIO undervalued or overvalued?
Based on our multi-method analysis, 3B BlackBio DX (3BBLACKBIO) appears to be trading above calculated value by approximately 62.6%.
Financial Health Analysis
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 22.00 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Debt to Equity Ratio | 1.09 | Industry Standard: <0.5 | Above 1.0 | Indicates financial leverage level |
| Return on Equity | 22.1% | Industry Standard: 15%+ | Above 15% | Measures shareholder return efficiency |
| Operating Margin | 43.0% | Industry Standard: 20%+ | Above 20% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.53x | Industry Standard: 1.0x+ | Above 0.5x | Measures asset utilization efficiency |
Related Pages for 3B BlackBio DX
Additional stock information and data for 3BBLACKBIO
Cash Flow Quality Analysis
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹43 Cr | ₹26 Cr | Positive Free Cash Flow | 8/10 |
| March 2024 | ₹27 Cr | ₹17 Cr | Positive Free Cash Flow | 8/10 |
| March 2023 | ₹20 Cr | ₹20 Cr | Positive Free Cash Flow | 8/10 |
| March 2022 | ₹37 Cr | ₹23 Cr | Positive Free Cash Flow | 8/10 |
| March 2021 | ₹98 Cr | ₹63 Cr | Positive Free Cash Flow | 8/10 |